Payment Terms for Intermediates: 7 Buyer Mistakes to Avoid
This guide compares T/T, L/C, D/P and D/A for pharmaceutical intermediate purchases, with worked costs on a $60,000 order and the seven mistakes buyers make.
blog
Impurity Fate Mapping: 5 Documents Buyers Should Request
An impurity absent from a Certificate of Analysis is not necessarily absent from the process — it may simply have been purged downstream. This guide explains impurity fate mapping, purge factors, ICH M7 Option 4, and the five documents buyers should request.
Dual Sourcing for API Intermediates: A Buyer’s Qualification Checklist
This checklist shows buyers how to qualify a second supplier in six steps — documentation, batch consistency, quality agreements, and activation triggers included.
Custom Synthesis vs Catalog Intermediates: A Buyer’s Decision Framework
This article presents a buyer’s decision framework built on six factors: specification match, lead time predictability, total cost of ownership, batch-to-batch consistency, documentation depth, and scale-up continuity.
The Hidden Cost of Switching Pharmaceutical Intermediate Suppliers: A Buyer’s Calculator
Switching intermediate suppliers for 20% lower price? Six hidden costs including bridging studies, regulatory filings, and method revalidation can reach $600K.
ICH Q2 Analytical Method Validation: What Your Intermediate COA Doesn’t Tell You
This guide decodes the seven validation parameters defined in ICH Q2(R2) from an intermediate buyer’s perspective, explains why stability-indicating methods matter for retest dating, and provides six questions buyers should ask suppliers about their analytical methods.
ICH Q11 Starting Material Selection: A Practical Guide for Pharmaceutical Intermediate Buyers
Learn how ICH Q11 starting material rules affect pharmaceutical intermediate sourcing—supplier boundaries, COA red flags, and a practical buyer’s checklist.
Polymorphism in Pharmaceutical Intermediates: Why Solid Form Control Matters
This guide explains what polymorphism means for intermediate buyers, how ICH Q6A Decision Tree #4 governs solid form control, which COA red flags signal polymorph gaps, and three questions every buyer should ask their supplier before committing to a purchase.
Elemental Impurities (ICH Q3D) in Pharmaceutical Intermediates: A Buyer’s Guide
This guide explains the four element classes, the 30% control threshold that determines whether routine testing is required, the difference between ICP-MS and ICP-OES analytical methods, and five red flags on supplier COAs that signal inadequate elemental impurity control.
Chiral Purity and Enantiomeric Excess (ee%) in Pharmaceutical Intermediates
This guide explains what ee% measures, why it differs from optical purity, how chiral HPLC validates stereochemical integrity, and which COA fields separate genuine process control from cosmetic data.